{"id":388145,"date":"2020-11-24T16:33:35","date_gmt":"2020-11-24T21:33:35","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=388145"},"modified":"2020-11-24T16:33:35","modified_gmt":"2020-11-24T21:33:35","slug":"stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/","title":{"rendered":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n BOSTON<\/span>, Nov. 24, 2020<\/span> \/PRNewswire\/ —\u00a0Stealth BioTherapeutics Corp\u00a0(Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of\u00a02,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company.\u00a0 The purchase price for one ADS was $1.125<\/span>.<\/p>\n

\n

\n
\n \"Stealth
\n <\/a>\n <\/p>\n<\/p><\/div>\n

H.C. Wainwright\u00a0& Co. acted as the exclusive placement agent for the offering.<\/p>\n

The gross proceeds from this offering were approximately\u00a0$3.2 million. <\/p>\n

The ADSs described above were offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020<\/span>. The ADSs were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A prospectus supplement and the accompanying prospectus relating to the offering of the ADSs were filed with the SEC on November 20, 2020<\/span>. Electronic copies of the prospectus supplement and the accompanying prospectus relating to the offering of ADSs may be obtained on the SEC’s website at http:\/\/www.sec.gov<\/a>\u00a0or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY<\/span> 10022, by e-mail: placements@hcwco.com<\/a>\u00a0or by telephone: (646) 975-6996.<\/p>\n

This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.<\/p>\n

\n About\u00a0Stealth<\/b>\n <\/p>\n

We are a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body’s main source of energy production and are critical for normal organ function.<\/p>\n

\n Investor Relations<\/b>\u00a0<\/p>\n

Stern Investor Relations
Janhavi Mohite<\/span>, 212-362-1200
IR@StealthBT.com<\/a><\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering-301180012.html<\/a><\/p>\n

SOURCE Stealth BioTherapeutics Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire BOSTON, Nov. 24, 2020 \/PRNewswire\/ —\u00a0Stealth BioTherapeutics Corp\u00a0(Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of\u00a02,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company.\u00a0 The purchase price for one ADS was $1.125. H.C. Wainwright\u00a0& Co. acted as the exclusive placement agent for the offering. The gross proceeds from this offering were approximately\u00a0$3.2 million. The ADSs described above were offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. … <\/p>\n

Continue reading “Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-388145","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nStealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire BOSTON, Nov. 24, 2020 \/PRNewswire\/ —\u00a0Stealth BioTherapeutics Corp\u00a0(Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of\u00a02,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company.\u00a0 The purchase price for one ADS was $1.125. H.C. Wainwright\u00a0& Co. acted as the exclusive placement agent for the offering. The gross proceeds from this offering were approximately\u00a0$3.2 million. The ADSs described above were offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. … Continue reading "Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-24T21:33:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering\",\"datePublished\":\"2020-11-24T21:33:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/\"},\"wordCount\":354,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/\",\"name\":\"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"datePublished\":\"2020-11-24T21:33:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/969361\\\/Stealth_BioTherapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/","og_locale":"en_US","og_type":"article","og_title":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk","og_description":"PR Newswire BOSTON, Nov. 24, 2020 \/PRNewswire\/ —\u00a0Stealth BioTherapeutics Corp\u00a0(Nasdaq: MITO) (“Stealth” or the “Company”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced the closing of its previously announced registered direct offering of\u00a02,844,446 of its American Depositary Shares (“ADSs”), each ADS representing 12 ordinary shares of the Company.\u00a0 The purchase price for one ADS was $1.125. H.C. Wainwright\u00a0& Co. acted as the exclusive placement agent for the offering. The gross proceeds from this offering were approximately\u00a0$3.2 million. The ADSs described above were offered pursuant to a “shelf” registration statement (File No. 333-237542) filed with the Securities and Exchange Commission (SEC) and declared effective on April 10, 2020. … Continue reading \"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-24T21:33:35+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering","datePublished":"2020-11-24T21:33:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/"},"wordCount":354,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/","name":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","datePublished":"2020-11-24T21:33:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/969361\/Stealth_BioTherapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/stealth-biotherapeutics-announces-closing-of-3-2-million-registered-direct-offering\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Stealth BioTherapeutics Announces Closing of $3.2 Million Registered Direct Offering"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388145","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=388145"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/388145\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=388145"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=388145"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=388145"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}